title: Eculizumab for the treatment of de novo thrombotic microangiopathy post simultaneous pancreas-kidney transplantation--a case report.
abstract: A 34-year-old female recipient of a simultaneous pancreas-kidney transplant presented 7 days posttransplant with acute renal allograft dysfunction, thrombocytopenia, and microangiopathic hemolytic anemia. Renal biopsy revealed acute antibody-mediated rejection (AMR) and acute thrombotic microangiopathy (TMA). Clinical and laboratory manifestations, which had only partly responded to treatment with daily plasma exchange and intravenous immunoglobulin, resolved rapidly and completely to eculizumab (Soliris, Alexion Pharmaceuticals, Inc., Cheshire, Conn), a complement factor C5 antibody. De novo posttransplant TMA is a rare and serious complication that can lead to graft loss in up to one third of cases. This is the first report of successful treatment of de novo TMA with eculizumab, which has previously shown benefit in recurrent atypical hemolytic uremic syndrome as well as in refractory acute AMR. Targeted complement inhibition offers the promise of a safe and effective therapeutic strategy in de novo TMA, especially in light of recent evidence suggesting that genetic mutations in complement regulatory proteins may predispose transplant recipients to this serious disease.
authors.affiliation: Department of Medicine, Division of Nephrology, Kidney Transplant Service, University of California San Francisco, California, USA.
authors.forename: S
authors.initials: S
authors.lastname: Chandran
authors.forename: L
authors.initials: L
authors.lastname: Baxter-Lowe
authors.forename: J L
authors.initials: JL
authors.lastname: Olson
authors.forename: S J
authors.initials: SJ
authors.lastname: Tomlanovich
authors.forename: A
authors.initials: A
authors.lastname: Webber
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D005260:Female; D006801:Humans; D016030:Kidney Transplantation / Q000009:adverse effects; D016035:Pancreas Transplantation / Q000009:adverse effects; D057049:Thrombotic Microangiopathies / Q000188:drug therapy* / Q000209:etiology
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C481642:eculizumab